A lot can change in five years, especially when someone has chronic thromboembolic pulmonary hypertension (CTEPH). A group of doctors at the University of Würzburg and Katharinen-Hospital Unna in Germany followed a 68-year-old woman for five years, from the time of her visiting the clinic with shortness of…
News
Actelion Ltd. will present the latest data from its pivotal phase III trial to evaluate selexipag (Uptravi) for the treatment of pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) Congress, which is taking place on March 15 in San Diego. The company…
In a recent study entitled “Prevalence and Impact of Pulmonary Hypertension on Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement,” a team of MDs reported that pulmonary hypertension (PH) is an independent factor capable of predicting patient outcomes after Transcatheter aortic valve replacement surgery. The…
In a new case-report study entitled “Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy,” authors describe vasodilators’ positive effects in treating Pulmonary Langerhans cell histiocytosis patients with known pulmonary hypertension. The study was published in the journal Respiratory Medicine…
In a new report entitled “Effect of Macitentan on Hospitalizations: Results From the SERAPHIN Trial,” researchers describe the benefits of a Macitentan 10 mg dose in reducing the risk for hospitalization in patients with symptomatic pulmonary arterial hypertension. The report was published in the journal of…
Courtesy of EchoSense A recent review on imaging of pulmonary vascular disease and the right ventricle by non-invasive techniques in the context of pulmonary arterial hypertension (PAH) was published in the Canadian Journal of Cardiology. The review entitled “Advanced imaging tools rather…
A French research team was able to demonstrate nebivolol’s beneficial effects in treating pulmonary arterial hypertension (PAH), suggesting that new clinical studies should be conducted to further test the drug. The study entitled: “Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function in Pulmonary Hypertension”…
Giving a Voice to Pulmonary Hypertension: First Entertainment Credit Union Features #PHAware Advocates Steve and Lucas Van Wormer (PRNewsFoto/First Entertainment Credit Union) Lucas Van Wormer, a thirteen-year-old voice actor with PH working at Cartoon Network, along with his father, partnered with a credit union to raise awareness for pulmonary…
A recent systematic review titled “Pregnancy and pulmonary arterial hypertension: A clinical conundrum,” highlights that pulmonary arterial hypertension (PAH) is an absolute contraindication for pregnant women. Pulmonary arterial hypertension (PAH) is a rare condition that causes progressive increases in pulmonary arterial pressure and pulmonary…
Patients with pulmonary hypertension who require a lung transplant are expected to move to higher priority on the wait list for a life-saving organ. On February 19, the Lung Allocation System, which is a means of prioritizing patients in need of a lung transplant, was…
According to a recent study published in the journal Heart, RV afterload increases in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during exercise, resulting in a marked reduction in RVEF and SV reserve. However, sildenafil may reverse this effect. In patients with…
Albuquerque-based Respira Therapeutics, Inc. is a biopharmaceutical company currently developing a dry powder inhaler drug delivery technology called AOS-DPI for RT234, a drug that is being designed to address pulmonary hypertension and other respiratory diseases such as IPF and COPD. In an effort to bolster the company’s commercialization efforts, they recently announced that Andy Clark has been appointed…
